Display options
Cite
Cavaliere V, Papademetrio DL, Lorenzetti M, et al. Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells. Transl Oncol. 2009;2(1):46-58doi: 10.1593/tlo.08202.
Cavaliere, V., Papademetrio, D. L., Lorenzetti, M., Valva, P., Preciado, M. V., Gargallo, P., Larripa, I., Monreal, M. B., Pardo, M. L., Hajos, S. E., Blanco, G. A., & Alvarez, E. M. (2009). Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells. Translational oncology, 2(1), 46-58. https://doi.org/10.1593/tlo.08202
Cavaliere, Victoria, et al. "Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells." Translational oncology vol. 2,1 (2009): 46-58. doi: https://doi.org/10.1593/tlo.08202
Cavaliere V, Papademetrio DL, Lorenzetti M, Valva P, Preciado MV, Gargallo P, Larripa I, Monreal MB, Pardo ML, Hajos SE, Blanco GA, Alvarez EM. Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells. Transl Oncol. 2009 Mar;2(1):46-58. doi: 10.1593/tlo.08202. PMID: 19252751; PMCID: PMC2647702.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2009 Mar;2(1):46-58. doi: 10.1593/tlo.08202.

Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells.

Translational oncology

Victoria Cavaliere, Daniela L Papademetrio, Mario Lorenzetti, Pamela Valva, María Victoria Preciado, Patricia Gargallo, Irene Larripa, Mariela B Monreal, María Laura Pardo, Silvia E Hajos, Guillermo Ac Blanco, Elida Mc Alvarez

Affiliations

  1. Instituto de Estudios de la Inmunidad Humoral "Prof. Ricardo A. Margni," CONICET, Departamento de Inmunología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.

PMID: 19252751 PMCID: PMC2647702 DOI: 10.1593/tlo.08202

Abstract

Chemotherapy aims to limit proliferation and induce apoptotic cell death in tumor cells. Owing to blockade of signaling pathways involved in cell survival and proliferation, nuclear factor kappaB (NF-kappaB) inhibitors can induce apoptosis in a number of hematological malignancies. The efficacy of conventional chemotherapeutic drugs, such as vincristine (VCR) and doxorubicine (DOX), may be enhanced with combined therapy based on NF-kappaB modulation. In this study, we evaluated the effect of caffeic acid phenylethyl ester (CAPE) and MG-132, two nonspecific NF-kappaB inhibitors, and conventional chemotherapeutics drugs DOX and VCR on cell proliferation and apoptosis induction on a lymphoblastoid B-cell line, PL104, established and characterized in our laboratory. CAPE and MG-132 treatment showed a strong antiproliferative effect accompanied by clear cell cycle deregulation and apoptosis induction. Doxorubicine and VCR showed antiproliferative effects similar to those of CAPE and MG-132, although the latter drugs showed an apoptotic rate two-fold higher than DOX and VCR. None of the four compounds showed cytotoxic effect on peripheral mononuclear cells from healthy volunteers. CAPE- and MG-132-treated bone marrow cells from patients with myeloid and lymphoid leukemias showed 69% (P < .001) and 25% decrease (P < .01) in cell proliferation and 42% and 34% (P < .01) apoptosis induction, respectively. Overall, our results indicate that CAPE and MG-132 had a strong and selective apoptotic effect on tumor cells that may be useful in future treatment of hematological neoplasias.

References

  1. Leukemia. 2008 Apr;22(4):842-9 - PubMed
  2. Z Naturforsch C J Biosci. 1995 Mar-Apr;50(3-4):167-72 - PubMed
  3. Mol Pharmacol. 2005 Sep;68(3):625-34 - PubMed
  4. Blood. 2000 Oct 1;96(7):2537-42 - PubMed
  5. Leukemia. 2006 Jan;20(1):61-7 - PubMed
  6. Biomed Pharmacother. 2004 Jul-Aug;58(6-7):365-71 - PubMed
  7. EMBO J. 1996 Sep 2;15(17):4682-90 - PubMed
  8. Mol Cancer Ther. 2004 Aug;3(8):985-92 - PubMed
  9. Nutr Cancer. 2003;47(2):156-63 - PubMed
  10. Science. 1996 Nov 1;274(5288):782-4 - PubMed
  11. Eur J Haematol. 2000 Oct;65(4):221-36 - PubMed
  12. J Biol Chem. 2004 Feb 13;279(7):6017-26 - PubMed
  13. Cancer Treat Rev. 2003 May;29 Suppl 1:11-9 - PubMed
  14. Biochem Biophys Res Commun. 2004 Nov 12;324(2):736-43 - PubMed
  15. Oncogene. 2004 Jul 29;23(34):5843-52 - PubMed
  16. Cancer Chemother Pharmacol. 2006 Apr;57(4):525-32 - PubMed
  17. Clin Cancer Res. 2004 May 15;10(10):3333-41 - PubMed
  18. Blood. 2002 Sep 1;100(5):1802-9 - PubMed
  19. Cancer Cell. 2004 May;5(5):417-21 - PubMed
  20. Leuk Res. 2005 Dec;29(12):1425-34 - PubMed
  21. Curr Med Chem. 2005;12(3):357-74 - PubMed
  22. J Virol. 2004 Apr;78(8):4108-19 - PubMed
  23. Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9090-5 - PubMed
  24. Mol Pharmacol. 2007 May;71(5):1369-80 - PubMed
  25. Blood. 2005 Dec 1;106(12):3917-25 - PubMed
  26. J Clin Invest. 1997 Dec 15;100(12):2952-60 - PubMed
  27. Cancer Lett. 2005 Jun 1;223(1):19-25 - PubMed
  28. Blood. 1996 Mar 1;87(5):1997-2004 - PubMed
  29. Genes Dev. 2004 Sep 15;18(18):2195-224 - PubMed
  30. Immunobiology. 2005;209(10):737-49 - PubMed
  31. Blood. 2007 Apr 1;109(7):2700-7 - PubMed
  32. Blood. 2003 Nov 1;102(9):3179-85 - PubMed
  33. Cancer Res. 1999 May 15;59(10):2347-52 - PubMed
  34. Biochem Pharmacol. 1994 Aug 3;48(3):595-608 - PubMed
  35. J Clin Oncol. 2005 Jan 20;23(3):630-9 - PubMed
  36. Nature. 2003 Aug 14;424(6950):797-801 - PubMed
  37. PLoS Pathog. 2007 Feb;3(2):e18 - PubMed
  38. J Mol Med (Berl). 2003 Apr;81(4):235-45 - PubMed
  39. J Agric Food Chem. 2001 Nov;49(11):5615-9 - PubMed
  40. Blood. 2004 Apr 15;103(8):3175-84 - PubMed
  41. Oncogene. 2007 Jun 14;26(28):4071-83 - PubMed
  42. Blood. 2006 Apr 15;107(8):3295-302 - PubMed
  43. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):80-8 - PubMed
  44. Nat Rev Immunol. 2002 Oct;2(10):725-34 - PubMed
  45. Nature. 2004 Sep 23;431(7007):461-6 - PubMed
  46. Haematologica. 2007 Sep;92(9):1224-9 - PubMed
  47. J Exp Med. 1989 Jun 1;169(6):2191-8 - PubMed
  48. Blood. 2006 Aug 1;108(3):1037-44 - PubMed
  49. BJU Int. 2004 Aug;94(3):402-6 - PubMed
  50. Cytometry. 1997 Jul 1;28(3):243-52 - PubMed
  51. Blood. 2003 Feb 1;101(3):1053-62 - PubMed

Publication Types